A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)

Phase 3

Completed

• Conditions: Pemphigus Vulgaris (PV)
• Interventions: Drug: Mycophenolate Mofetil (MMF) 3 g/Day; Drug: Mycophenolate Mofetil 2 g/Day; Drug: Placebo

• Registration Number: NCT00683930
• Lead Sponsor: Hoffmann-La Roche

Brief Summary

This study was designed to assess the efficacy and safety of CellCept (1 g or 1.5 g orally twice daily for 52 weeks) in patients with pemphigus vulgaris receiving prednisone or other corticosteroids. During the study, patients had their corticosteroid dose gradually reduced if they responded to treatment. The anticipated time on study treatment was 12 months, and the target sample size was \<100 individuals.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design

Study Timeline

• Study Start: 2004-05
• Study First Submitted: 2008-05-19
• Study First Submitted QC: 2008-05-23
• Study First Posted: 2008-05-26
• Primary Completion: 2008-10
• Study Completion: 2008-10
• Results First Submitted: 2009-11-18
• Status Verified: 2011-05
• Results First Submitted QC: 2011-05-25
• Last Update Submitted: 2011-05-25
• Results First Posted: 2011-06-22
• Last Update Posted: 2011-06-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 96

Inclusion Criteria

• Adult patients 18 to 70 years of age
• Diagnosis of mild to moderate pemphigus vulgaris within the past 12 months, requiring high dose corticosteroids

Read More

Exclusion Criteria

• Female patients who are pregnant, breastfeeding, or lactating
• Regularly scheduled plasma exchange (PE) or intravenous immunoglobulin (IVIG) treatment, or PE or IVIG treatment within 8 weeks prior to randomization
• CellCept or other immunosuppressive therapy, except corticosteroids, exceeding 2 weeks total duration and within 8 weeks prior to randomization
• Use of PV therapies other than those noted above, within 4 weeks prior to randomization
• Use of topical corticosteroids within 2 weeks prior to randomization

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Mycophenolate Mofetil (MMF) 3 g/Day	Mycophenolate Mofetil (MMF) 3 g/Day	Mycophenolate mofetil 500 mg tablets; 6 tablets twice daily for 52 weeks
Mycophenolate Mofetil (MMF) 2 g/Day	Mycophenolate Mofetil 2 g/Day	Mycophenolate mofetil 500 mg tablets; 4 tablets twice daily for 52 weeks
Placebo	Placebo	-

Primary Outcome Measures

Name	Time	Method
Percentage of Patients Achieving Responder Status at Week 52	52 weeks	The proportion of subjects achieving responder status (defined as no new persistent lesions and prednisone dose of not more than 10 mg/day from Week 48 until study termination at Week 52) in the two active treatment groups combined (2 g/day and 3 g/day mycophenolate mofetil) compared with the placebo group

Secondary Outcome Measures

Name	Time	Method
Time to Initial Response	up to 52 weeks	Time to initial response defined as the time that the subject first demonstrated responder status (defined as no new persistent lesions and prednisone dose of not more than 10 mg/day from Week 48 until study termination at Week 52)
Time to Sustained Response	up to 52 weeks	Time to sustained response is defined as the week the subject first demonstrates both of the conditions of responder status provided the conditions are maintained through to study termination at Week 52. If a subject does not have a sustained response, time to sustained response is censored on the last day of the study.
Duration of Prednisone Maintenance Dosing	52 weeks	The duration of prednisone maintenance dosing was defined as the number of days that subjects maintained a prednisone dose of not more than 10 mg/day in the absence of new persistent lesions.